1. Medtech Insight
  2. >>Business
  3. >>Financing

Digital Platform Caresyntax Extends Series C To Total $130M Raised

 
• By Marion Webb

Caresyntax raised $130m in total funding to expand commercialization of its software that seeks to reduce variability and improve outcomes in the operating room.

Surgicaldata

Caresyntax Corp., a developer of a digital platform intended to reduce surgery-related complications, added $30 million to its earlier series C round, bringing the total funding raised to $130m. Among the new investors are funds and accounts managed by BlackRock and health insurer ProAssurance, venture capital firm Harmonix and existing backers such as Releyns Group, Europe’s largest medical malpractice insurer, and IPF Partners, Caresyntax said in a 16 September announcement.

The added investment builds on the first stage, announced in April, that was led by PFM Health Sciences, LP and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Medtech M&A Resurges: How To Define Startup Exit Strategy

 
• By Natasha Barrow

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.

Intuitive Surgical Sees Early Wins With Da Vinci 5, Lifts FY25 Guidance As Tariff Impact Eases

 
• By Shubham Singh

For the full year, the company now expects tariffs to increase the cost of sales by approximately 1% of revenue, plus or minus 20 basis points. This is lower than the previous estimate of approximately 1.7% of revenue. The updated gross margin guidance for 2025 is 66%-67%, up from 65%-66.5%.

Private Equity Firm Archimed To Buy ZimVie As Antitrust Concerns Sideline Strategic Buyers

 
• By Marion Webb

Archimed will acquire dental implant firm ZimVie for $730m in a deal that reflects private equity’s growing role in medtech M&A, as strategic buyers face antitrust scrutiny. The deal includes a 125% premium and a 40-day window for competing offers.